Bio Key International Stock Cash And Equivalents
BKYI Stock | USD 1.50 0.06 4.17% |
BIO Key International fundamentals help investors to digest information that contributes to BIO Key's financial success or failures. It also enables traders to predict the movement of BIO Stock. The fundamental analysis module provides a way to measure BIO Key's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIO Key stock.
BIO | Cash And Equivalents |
BIO Key International Company Cash And Equivalents Analysis
BIO Key's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current BIO Key Cash And Equivalents | 4.89 M |
Most of BIO Key's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIO Key International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BIO Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for BIO Key is extremely important. It helps to project a fair market value of BIO Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since BIO Key's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BIO Key's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BIO Key's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
BIO Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, BIO Key International has 4.89 M in Cash And Equivalents. This is 98.76% lower than that of the Software sector and 94.3% lower than that of the Information Technology industry. The cash and equivalents for all United States stocks is 99.82% higher than that of the company.
BIO Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIO Key's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIO Key could also be used in its relative valuation, which is a method of valuing BIO Key by comparing valuation metrics of similar companies.BIO Key is currently under evaluation in cash and equivalents category among its peers.
BIO Fundamentals
Return On Equity | -4.58 | ||||
Return On Asset | -0.56 | ||||
Profit Margin | (0.92) % | ||||
Operating Margin | (1.45) % | ||||
Current Valuation | 6.02 M | ||||
Shares Outstanding | 3.11 M | ||||
Shares Owned By Insiders | 5.57 % | ||||
Shares Owned By Institutions | 5.02 % | ||||
Number Of Shares Shorted | 76 K | ||||
Price To Earning | (2.55) X | ||||
Price To Book | 40.29 X | ||||
Price To Sales | 0.77 X | ||||
Revenue | 7.75 M | ||||
Gross Profit | 3.44 M | ||||
EBITDA | (7.85 M) | ||||
Net Income | (8.52 M) | ||||
Cash And Equivalents | 4.89 M | ||||
Cash Per Share | 0.58 X | ||||
Total Debt | 365.35 K | ||||
Debt To Equity | 0.05 % | ||||
Current Ratio | 3.50 X | ||||
Book Value Per Share | (0.58) X | ||||
Cash Flow From Operations | (3.79 M) | ||||
Short Ratio | 0.16 X | ||||
Earnings Per Share | (8.66) X | ||||
Target Price | 3.0 | ||||
Number Of Employees | 43 | ||||
Beta | 0.25 | ||||
Market Capitalization | 3.25 M | ||||
Total Asset | 4.52 M | ||||
Retained Earnings | (125.01 M) | ||||
Working Capital | (591.23 K) | ||||
Current Asset | 9.88 M | ||||
Current Liabilities | 1.72 M | ||||
Net Asset | 4.52 M |
About BIO Key Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIO Key International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIO Key using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIO Key International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Check out BIO Key Piotroski F Score and BIO Key Altman Z Score analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Systems Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIO Key. If investors know BIO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIO Key listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.66) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of BIO Key International is measured differently than its book value, which is the value of BIO that is recorded on the company's balance sheet. Investors also form their own opinion of BIO Key's value that differs from its market value or its book value, called intrinsic value, which is BIO Key's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIO Key's market value can be influenced by many factors that don't directly affect BIO Key's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIO Key's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIO Key is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIO Key's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.